AMARIN CORP PLC\UK Deferred Foreign Income Tax Expense (Benefit)
AMARIN CORP PLC\UK (AMRN) reported Deferred Foreign Income Tax Expense (Benefit) of $1.31 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredForeignIncomeTaxExpenseBenefit · last filed 2026-03-02
- AMARIN CORP PLC\UK deferred foreign income tax expense (benefit) for fiscal 2025 was $1.31M.
- AMARIN CORP PLC\UK deferred foreign income tax expense (benefit) for fiscal 2024 was -$11.51M.
- AMARIN CORP PLC\UK deferred foreign income tax expense (benefit) for fiscal 2023 was -$15.41M.
- AMARIN CORP PLC\UK deferred foreign income tax expense (benefit) for fiscal 2022 was -$1.65M.
| Period end | Deferred Foreign Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $1.31M 10-K · filed 2026-03-02 |
| 2024-12-31 | -$11.51M 10-K · filed 2026-03-02 |
| 2023-12-31 | -$15.41M 10-K · filed 2026-03-02 |
| 2022-12-31 | -$1.65M 10-K · filed 2025-03-12 |
| 2021-12-31 | -$1.62M 10-K · filed 2024-02-29 |
| 2020-12-31 | -$26.79M 10-K · filed 2023-03-01 |
| 2019-12-31 | $1.28M 10-K · filed 2022-03-01 |
| 2018-12-31 | -$5.43M 10-K · filed 2021-02-25 |
| 2017-12-31 | -$16.31M 10-K · filed 2020-02-25 |
| 2016-12-31 | -$143.00K 10-K · filed 2019-02-27 |
| 2015-12-31 | -$9.02M 10-K · filed 2018-02-27 |
| 2014-12-31 | $3.33M 10-K · filed 2017-03-01 |
| 2013-12-31 | -$33.11M 10-K · filed 2016-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |